To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery specialist Genevant Sciences…

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…

Omeros is putting up its monoclonal antibody up for FDA approval—again. This time, the resubmission will be based on a…

After hitting the mark in a phase 2 of its investigational islatravir paired with Gilead’s lenacapivir, Merck & Co.'s islatravir…

KdT Ventures has signed off on a $608 million biobucks deal for NGM Biopharmaceuticals’ phase 2-ready metabolic-dysfunction associated steatohepatitis (MASH)…

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial,…

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval…

Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in…

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 million…

Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein. Days after UCB reported the…